Calling all clinicians, clinician-scientists and biomedical researchers to complete the 'State of Endocrinology 2025 Survey' - this is your chance to raise your voice!
A widely used hormone treatment, Cyproterone acetate (CPA), has come under scrutiny following studies linking high-dose or long-term use to a sharply increased risk of meningioma, a type of brain tumor. European research suggests a 6- to 20-fold rise in risk, potentially due to the drug's stimulation of hormone receptors found in certain brain regions.
This one-day national educational event has been developed by members of the national British Society of Paediatric Endocrinology and Diabetes (BSPED) Growth Disorder Special Interest Group to directly address an unmet educational need in in this field of paediatric endocrinology.